Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.050
-0.080 (-1.94%)
At close: Aug 13, 2025, 4:00 PM
4.000
-0.050 (-1.23%)
Pre-market: Aug 14, 2025, 9:11 AM EDT
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $1.56M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $1.86M, up 572.56% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$1.86M
Revenue Growth
+572.56%
P/S Ratio
461.18
Revenue / Employee
$34,500
Employees
54
Market Cap
859.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ATAI News
- 16 days ago - Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus - Seeking Alpha
- 16 days ago - Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
- 17 days ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 19 days ago - Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial - Reuters
- 19 days ago - Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia - GlobeNewsWire
- 6 weeks ago - Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD - Seeking Alpha
- 6 weeks ago - Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data - Benzinga
- 6 weeks ago - atai Life Sciences Announces $50 Million Private Placement Financing - GlobeNewsWire